Effets cardio-metaboliques du rimonabant chez le sujet obese ou en surpoids avec dyslipidemie ou diabete de type 2.

Anti-Obesity Agents/therapeutic use; Bradykinin/antagonists & inhibitors; Cannabinoids/antagonists & inhibitors; Cholesterol, HDL/drug effects; Diabetes Mellitus, Type 2/complications/metabolism; Dyslipidemias/complications/metabolism; Follow-Up Studies; Heart/drug effects; Hemoglobin A, Glycosylated/drug effects; Humans; Insulin Resistance; Metabolic Syndrome X/prevention & control; Obesity/drug therapy; Overweight/drug effects; Piperidines/therapeutic use; Placebos; Pyrazoles/therapeutic use; Receptor, Cannabinoid, CB1/antagonists & inhibitors; Risk Factors; Triglycerides/analysis; Waist-Hip Ratio; Weight Loss/drug effects

Abstract :

[en] Rimonabant (Acomplia) is the first selective CB1 receptor blocker of the endocannabinoid system. It has been evaluated in the RIO ("Rimonabant In Obesity and related disorders") programme including above 6.600 overweight/obese patients with or without comorbidities followed for 1 to 2 years. Compared to placebo, rimonabant 20 mg/day consistently increases weight loss, reduces waist circumference, increases HDL cholesterol, lowers triglyceride levels, diminishes insulin resistance, and reduces the prevalence of metabolic syndrome. In patients with type 2 diabetes, rimonabant also diminishes HbA1c levels, an effect confirmed in the recent SERENADE trial. Almost half of the metabolic effects occurs beyond weight loss, suggesting direct peripheral effects of rimonabant. Rimonabant is indicated in Europe as an adjunct to diet and exercise for the treatment of obese patients, or overweight patients with associated risk factor(s), such as type 2 diabetes or dyslipidaemia.

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Van Gaal, L. F.

Language :

French

Title :

Effets cardio-metaboliques du rimonabant chez le sujet obese ou en surpoids avec dyslipidemie ou diabete de type 2.

Alternative titles :

[en] Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes

Publication date :

2007

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

81-5

Peer reviewed :

Peer reviewed

Additional URL :

http://www.rmlg.ulg.ac.be/index.php?page=resume?num_id=1543&langue=FR

Available on ORBi :

since 13 January 2009

Statistics

Number of views

446 (6 by ULiège)

Number of downloads

435 (7 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Després JP, Lemieux I. - Abdominal obesity and metabolic syndrome. Nature, 2006, 444, 881-887.
Van Gaal LF, Mertens IL, De Block CE. - Mechanisms linking obesity with cardiovascular disease. Nature, 2006, 444, 875-880.
Scheen AJ. - Current management strategies for coexisting diabetes mellitus and obesity. Drugs, 2003, 63, 1165-1184.
Klein S, Burke LE, Bray GA, et al. - Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation, 2004, 110, 2952-2967.
Grundy SM, Cleeman JI, Daniels SR, et al. - Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 2005. 112, 2735-2752.
Padwal RS, Majumdar SR. - Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet, 2007, 369, 71-77.
Di Marzo V, Bifulco M, De Petrocellis L. - The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov, 2004, 3, 771-784.
Pagotto U, Marsicano G, Cota D, et al. - The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev, 2006, 27, 73-100.
Van Gaal LF, Rissanen AM, Scheen AJ, et al. - Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients : 1-year experience from the RIO-Europe study. Lancet, 2005, 365, 1389-1397.
Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. - Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America : a randomized controlled trial. JAMA, 2006, 295, 761-775.
Després JP, Golay A, Sjöström L, Rimonabant in Obesity-Lipids Study Group. - Effects on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med, 2005, 353, 2121-2134.
Scheen AJ, Finer N, Hollander P, et al for the RIO-Diabetes Study Group. - Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled studv. Lancet, 2006, 368, 1660-1672.
Scheen AJ, Van Gaal LG, Després J-P, et al. - Le rimonabant améliore le profil de risque cardio-métabolique chez le sujet obèse ou en surpoids : synthèse des études «RIO». Rev Med Suisse, 2006, 2, 1916-1923.
Gadde KM, Allison DB. - Cannabiboid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation, 2006, 114, 974-984.
Curioni C, Andre C. - Rimonabant for overweight or obesity. Cochrane Database of Systematic Reviews, 2006, 4, 4.
Scheen AJ, Van Gaal LF. - Le diabète de type 2 au coeur du syndrome métabolique : plaidoyer pour une prise en charge globale. Rev Med Liège, 2005, 60, 566-571.
Iranmanesh A, Rosenstock J, Hollander P, SERENADE-Study-Group. - SERENADE : Rimonabant monotherapy for treatment of multiple cardiometabolic risk factors in treatment-naïve patients with type 2 diabetes (abstract). Diabet Med, 2006, 23 (Suppl 4), 230.
Pi-Sunyer F-X, Després J-P, Scheen A, Van Gaal L. - Improvement of metabolic effects with rimonabant beyond the effect attributable to weight loss alone : pooled one year data from the RIO (Rimonabant In Obesity and Related Metabolic Disorders) program (abstract). JACC, 2006, 47 (Suppl A), 362-A.
Stratton IM, Adler AI, Neil HA, et al. - Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000, 321, 405-412.